The high variability of the HIV envelope glycoproteins (Env), and their heavy glycan coating, contributes to the limited host immune control. Still, broadly neutralizing antibodies (bnAbs) are found in some chronically infected HIV-infected individuals, which has spurred the research on antibody-based vaccines. An important tool in detecting and studying bnAbs, are neutralization assays. Here we developed an image-based, high-content automated version of a plaque reduction (PR) assay, which uses green fluorescent protein expression as a reporter of HIV infection. This permitted simultaneous detection of antibodies mediating neutralization and inhibition of virus induced cell-cell fusion. In a multicenter study, Neutnet II, the assay compare...
Sexual transmission of HIV-1 requires virus adsorption to a target cell, typically a CD4 T lymphocy...
Identifying molecular targets for eliciting broadly virus-neutralizing antibodies is one of the key ...
This work is licensed under a Creative Commons Attribution Non-Commercial-No Derivatives 4.0 Interna...
<div><p>The extensive glycosylation of HIV-1 envelope (Env) glycoprotein leaves few glycan-free hole...
The extensive glycosylation of HIV-1 envelope (Env) glycoprotein leaves few glycan-free holes large ...
The HIV-1 envelope glycoprotein (Env) is the sole target for HIV broadly neutralizing antibodies (bn...
Human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2) are the etiological agents of AIDS in h...
© 2017 Dr Christopher Andrew GonelliA prophylactic vaccine eliciting broadly neutralising antibody (...
Objective: An effective HIV vaccine must be able to block infection by a wide range of viral isolate...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
AbstractFollowing primary infection with human immunodeficiency virus type-1 (HIV-1), macrophages ar...
Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are p...
Extensive shielding by N-glycans on the surface of the HIV envelope glycoproteins (Env) restricts B ...
The first step in the entry of HIV-1 is the binding of the viral envelope glycoprotein (gp120) to ...
AbstractThe human immunodeficiency virus (HIV-1) exterior envelope glycoprotein, gp120, mediates rec...
Sexual transmission of HIV-1 requires virus adsorption to a target cell, typically a CD4 T lymphocy...
Identifying molecular targets for eliciting broadly virus-neutralizing antibodies is one of the key ...
This work is licensed under a Creative Commons Attribution Non-Commercial-No Derivatives 4.0 Interna...
<div><p>The extensive glycosylation of HIV-1 envelope (Env) glycoprotein leaves few glycan-free hole...
The extensive glycosylation of HIV-1 envelope (Env) glycoprotein leaves few glycan-free holes large ...
The HIV-1 envelope glycoprotein (Env) is the sole target for HIV broadly neutralizing antibodies (bn...
Human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2) are the etiological agents of AIDS in h...
© 2017 Dr Christopher Andrew GonelliA prophylactic vaccine eliciting broadly neutralising antibody (...
Objective: An effective HIV vaccine must be able to block infection by a wide range of viral isolate...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
AbstractFollowing primary infection with human immunodeficiency virus type-1 (HIV-1), macrophages ar...
Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are p...
Extensive shielding by N-glycans on the surface of the HIV envelope glycoproteins (Env) restricts B ...
The first step in the entry of HIV-1 is the binding of the viral envelope glycoprotein (gp120) to ...
AbstractThe human immunodeficiency virus (HIV-1) exterior envelope glycoprotein, gp120, mediates rec...
Sexual transmission of HIV-1 requires virus adsorption to a target cell, typically a CD4 T lymphocy...
Identifying molecular targets for eliciting broadly virus-neutralizing antibodies is one of the key ...
This work is licensed under a Creative Commons Attribution Non-Commercial-No Derivatives 4.0 Interna...